Novo Obesity Shot Wegovy Helped Alcoholics Drink Less in Study

April 30, 2026, 10:30 PM UTC

Novo Nordisk A/S’s obesity shot Wegovy helped people with alcoholism reduce their drinking, in the first controlled study of patients who sought help with their addiction.

Volunteers on Wegovy reported drinking heavily for five days in a 30-day period after six months of treatment, 12 fewer days than before they started. The improvement showed in other measures of addiction, such as total alcohol consumption and bloodwork.

“This was totally the dream scenario,” said Mette Kruse Klausen, a doctor and researcher at the Mental Health Center Copenhagen and one of the leaders of the study. “This is very robust results ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.